These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Sunitinib but not VEGF blockade inhibits cancer stem cell endothelial differentiation. Brossa A; Grange C; Mancuso L; Annaratone L; Satolli MA; Mazzone M; Camussi G; Bussolati B Oncotarget; 2015 May; 6(13):11295-309. PubMed ID: 25948774 [TBL] [Abstract][Full Text] [Related]
4. Sunitinib reduces tumor hypoxia and angiogenesis, and radiosensitizes prostate cancer stem-like cells. Diaz R; Nguewa PA; Redrado M; Manrique I; Calvo A Prostate; 2015 Aug; 75(11):1137-49. PubMed ID: 25893276 [TBL] [Abstract][Full Text] [Related]
5. CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer. Conley SJ; Baker TL; Burnett JP; Theisen RL; Lazarus D; Peters CG; Clouthier SG; Eliasof S; Wicha MS Breast Cancer Res Treat; 2015 Apr; 150(3):559-67. PubMed ID: 25833208 [TBL] [Abstract][Full Text] [Related]
6. Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice. Maione F; Capano S; Regano D; Zentilin L; Giacca M; Casanovas O; Bussolino F; Serini G; Giraudo E J Clin Invest; 2012 May; 122(5):1832-48. PubMed ID: 22484816 [TBL] [Abstract][Full Text] [Related]
8. Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastatis. Kerbel RS; Guerin E; Francia G; Xu P; Lee CR; Ebos JM; Man S Breast; 2013 Aug; 22 Suppl 2():S57-65. PubMed ID: 24074794 [TBL] [Abstract][Full Text] [Related]
9. Antiangiogenic agents targeting different angiogenic pathways have opposite effects on tumor hypoxia in R-18 human melanoma xenografts. Gaustad JV; Simonsen TG; Andersen LMK; Rofstad EK BMC Cancer; 2017 Jun; 17(1):411. PubMed ID: 28606060 [TBL] [Abstract][Full Text] [Related]
10. Targeting both HIF-1 and HIF-2 in human colon cancer cells improves tumor response to sunitinib treatment. Burkitt K; Chun SY; Dang DT; Dang LH Mol Cancer Ther; 2009 May; 8(5):1148-56. PubMed ID: 19435875 [TBL] [Abstract][Full Text] [Related]
11. A model of postsurgical advanced metastatic breast cancer more accurately replicates the clinical efficacy of antiangiogenic drugs. Guerin E; Man S; Xu P; Kerbel RS Cancer Res; 2013 May; 73(9):2743-8. PubMed ID: 23610448 [TBL] [Abstract][Full Text] [Related]
12. Dopamine enhances the response of sunitinib in the treatment of drug-resistant breast cancer: Involvement of eradicating cancer stem-like cells. Wang S; Mou Z; Ma Y; Li J; Li J; Ji X; Wu K; Li L; Lu W; Zhou T Biochem Pharmacol; 2015 May; 95(2):98-109. PubMed ID: 25824241 [TBL] [Abstract][Full Text] [Related]
13. Anti-angiogenic treatment promotes triple-negative breast cancer invasion via vasculogenic mimicry. Sun H; Zhang D; Yao Z; Lin X; Liu J; Gu Q; Dong X; Liu F; Wang Y; Yao N; Cheng S; Li L; Sun S Cancer Biol Ther; 2017 Apr; 18(4):205-213. PubMed ID: 28278077 [TBL] [Abstract][Full Text] [Related]
14. Targeting of the breast cancer microenvironment with a potent and linkable oxindole based antiangiogenic small molecule. Argyros O; Karampelas T; Varela A; Asvos X; Papakyriakou A; Agalou A; Beis D; Davos CH; Fokas D; Tamvakopoulos C Oncotarget; 2017 Jun; 8(23):37250-37262. PubMed ID: 28422745 [TBL] [Abstract][Full Text] [Related]
16. HIF-1α activation mediates resistance to anti-angiogenic therapy in neuroblastoma xenografts. Hartwich J; Orr WS; Ng CY; Spence Y; Morton C; Davidoff AM J Pediatr Surg; 2013 Jan; 48(1):39-46. PubMed ID: 23331791 [TBL] [Abstract][Full Text] [Related]
17. Multiple receptor tyrosine kinases regulate HIF-1alpha and HIF-2alpha in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors. Nilsson MB; Zage PE; Zeng L; Xu L; Cascone T; Wu HK; Saigal B; Zweidler-McKay PA; Heymach JV Oncogene; 2010 May; 29(20):2938-49. PubMed ID: 20208561 [TBL] [Abstract][Full Text] [Related]
18. Stem-like tumor cells involved in heterogeneous vasculogenesis in breast cancer. Mao Y; Zhu L; Huang Z; Luo C; Zhou T; Li L; Wang G; Yang Z; Qi W; Yang X; Gao G Endocr Relat Cancer; 2020 Jan; 27(1):23-39. PubMed ID: 31705798 [TBL] [Abstract][Full Text] [Related]
19. Distinct breast cancer stem/progenitor cell populations require either HIF1α or loss of PHD3 to expand under hypoxic conditions. Iriondo O; Rábano M; Domenici G; Carlevaris O; López-Ruiz JA; Zabalza I; Berra E; Vivanco Md Oncotarget; 2015 Oct; 6(31):31721-39. PubMed ID: 26372732 [TBL] [Abstract][Full Text] [Related]
20. Hypoxia-inducible factors promote breast cancer stem cell specification and maintenance in response to hypoxia or cytotoxic chemotherapy. Xiang L; Semenza GL Adv Cancer Res; 2019; 141():175-212. PubMed ID: 30691683 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]